FUMAROLA, Claudia
 Distribuzione geografica
Continente #
EU - Europa 262
NA - Nord America 120
AS - Asia 101
AF - Africa 8
SA - Sud America 2
OC - Oceania 1
Totale 494
Nazione #
IT - Italia 135
US - Stati Uniti d'America 116
IE - Irlanda 52
CN - Cina 23
DE - Germania 22
IN - India 18
GB - Regno Unito 13
KR - Corea 13
JP - Giappone 11
TW - Taiwan 9
NL - Olanda 6
VN - Vietnam 6
FR - Francia 5
FI - Finlandia 4
MY - Malesia 4
RU - Federazione Russa 4
BE - Belgio 3
CA - Canada 3
EG - Egitto 3
ES - Italia 3
HK - Hong Kong 3
HU - Ungheria 3
ID - Indonesia 3
SE - Svezia 3
AT - Austria 2
CH - Svizzera 2
DZ - Algeria 2
KZ - Kazakistan 2
SC - Seychelles 2
SG - Singapore 2
TR - Turchia 2
AU - Australia 1
BO - Bolivia 1
BR - Brasile 1
BY - Bielorussia 1
CZ - Repubblica Ceca 1
IR - Iran 1
MO - Macao, regione amministrativa speciale della Cina 1
MX - Messico 1
NO - Norvegia 1
PK - Pakistan 1
PT - Portogallo 1
SA - Arabia Saudita 1
TH - Thailandia 1
UA - Ucraina 1
UG - Uganda 1
Totale 494
Città #
Dublin 51
Parma 51
Arezzo 16
Ann Arbor 12
Ashburn 10
Boardman 10
Medolla 9
Yongsan 7
Milan 6
Suita 6
Casarano 5
Neviano degli Arduini 5
Bremen 4
Brooklyn 4
Dong Ket 4
Guangzhou 4
Hangzhou 4
Helsinki 4
Indianapolis 4
Rome 4
Xian 4
Beijing 3
Detroit 3
Fleming Island 3
Gent 3
Hartford 3
Houston 3
Leonia 3
London 3
Paris 3
Shanghai 3
Southend 3
Taipei 3
Washington 3
Waterville 3
Amstelveen 2
Bangalore 2
Casina 2
Central District 2
Concord 2
Council Bluffs 2
Danbury 2
Delhi 2
Gladbeck 2
Hyderabad 2
Jijelli 2
Los Angeles 2
Madrid 2
Pittsburgh 2
Reggio Nell'emilia 2
Roselle 2
Sant'ilario D'enza 2
Seoul 2
Serra 2
Slough 2
Szeged 2
Vadodara 2
Vienna 2
Ahmedabad 1
Aktobe 1
Bacoli 1
Baltimore 1
Bengaluru 1
Bhavnagar 1
Borås 1
Boston 1
Bromma 1
Cagliari 1
Casalgrande 1
Castelfranco Emilia 1
Chandigarh 1
Chengdu 1
Chennai 1
Cincinnati 1
Cochabamba 1
Dallas 1
East Syracuse 1
Edmonton 1
Ferrara 1
Frederick 1
Gainesville 1
Garching 1
Genoa 1
Genova 1
Hanoi 1
Harada 1
Islamabad 1
Kansas City 1
Konstanz 1
Lake Forest 1
Lexington 1
Mcallen 1
Memphis 1
Menlo Park 1
Milpitas 1
Minneapolis 1
Modena 1
Montale 1
Monterrey 1
Moscow 1
Totale 354
Nome #
Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer, file e177fbc4-42b8-50b0-e053-d805fe0adaee 120
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib, file e177fbc7-275c-50b0-e053-d805fe0adaee 36
New therapeutic strategies for malignant pleural mesothelioma, file e177fbc7-6d9a-50b0-e053-d805fe0adaee 36
null, file e177fbc4-3a65-50b0-e053-d805fe0adaee 28
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer, file e177fbc6-c828-50b0-e053-d805fe0adaee 28
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer, file e177fbc4-374a-50b0-e053-d805fe0adaee 26
Anti-proliferative effects of copper(II) complexes with hydroxyquinoline-thiosemicarbazone ligands, file e177fbc7-5309-50b0-e053-d805fe0adaee 25
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells., file e177fbc5-d274-50b0-e053-d805fe0adaee 22
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines, file e177fbc5-e007-50b0-e053-d805fe0adaee 19
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC, file e177fbc6-8be1-50b0-e053-d805fe0adaee 17
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines, file e177fbc4-3e0a-50b0-e053-d805fe0adaee 16
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines, file e177fbc5-2589-50b0-e053-d805fe0adaee 13
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells, file e177fbc6-9bb6-50b0-e053-d805fe0adaee 12
Anti-proliferative effects of copper(II) complexes with hydroxyquinoline-thiosemicarbazone ligands, file e177fbc5-5fdc-50b0-e053-d805fe0adaee 11
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines., file e177fbc6-8938-50b0-e053-d805fe0adaee 11
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion, file e177fbc7-5975-50b0-e053-d805fe0adaee 11
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation, file e177fbc7-5aef-50b0-e053-d805fe0adaee 9
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib, file e177fbc4-3d29-50b0-e053-d805fe0adaee 7
New therapeutic strategies for malignant pleural mesothelioma, file e177fbc5-6e69-50b0-e053-d805fe0adaee 6
Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation, file e177fbc7-1d2f-50b0-e053-d805fe0adaee 5
Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation, file e177fbc7-5af1-50b0-e053-d805fe0adaee 5
Synergistic activity of letrozole and sorafenib on breast cancer cells, file e177fbc4-1f38-50b0-e053-d805fe0adaee 4
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors), file e177fbc4-2810-50b0-e053-d805fe0adaee 4
Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lung, file e177fbc4-8054-50b0-e053-d805fe0adaee 4
Physico-chemical characterization and biological evaluation of two fibroin materials, file e177fbc5-1a5a-50b0-e053-d805fe0adaee 3
Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer, file d9ef1511-b26b-4ec8-a599-23a03fa4141c 2
Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines, file e177fbc4-1f39-50b0-e053-d805fe0adaee 2
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN, file e177fbc5-953c-50b0-e053-d805fe0adaee 2
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells, file e177fbc6-03ea-50b0-e053-d805fe0adaee 2
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation, file e177fbc7-56f9-50b0-e053-d805fe0adaee 2
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells, file e177fbc7-a024-50b0-e053-d805fe0adaee 2
Impairing energy metabolism in solid tumors through agents targeting oncogenic signaling pathways, file e177fbc7-a69a-50b0-e053-d805fe0adaee 2
Increased level of inducible HSP70 in cells exposed to electromagnetic fields., file e177fbc4-0e60-50b0-e053-d805fe0adaee 1
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification, file e177fbc4-3c48-50b0-e053-d805fe0adaee 1
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations., file e177fbc4-8faf-50b0-e053-d805fe0adaee 1
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR, file e177fbc7-ab25-50b0-e053-d805fe0adaee 1
Totale 496
Categoria #
all - tutte 1.161
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.161


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201 0 1 0 0 0 0 0 0 0 0 0 0
2020/202116 0 0 0 0 0 1 0 1 3 0 2 9
2021/202289 4 20 3 9 4 2 20 4 4 5 5 9
2022/2023166 10 2 2 4 7 6 6 11 82 7 20 9
2023/202428 8 5 5 10 0 0 0 0 0 0 0 0
Totale 496